Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Alnylam Pharmaceuticals announced that its Board of Directors authorized a new $1.0 billion share repurchase program. The company expects to repurchase approximately $500 million of its common stock by the end of 2026, with the remaining balance planned for 2027. Additionally, the company disclosed that Tolga Tanguler will depart from his role as Executive Vice President and Chief Commercialization Officer in December 2026.
Crh Public Ltd Insider Siobhan Talbot Buys $189K of Stock
Siobhan Talbot bought 2,000 shares of Crh Public Ltd Co at $94.63 a share, worth $189K in total on Nov 3, 2026. Shares held after the trade: 10,507 (+23.5%).
SAB Biotherapeutics reported a net loss of $22.3 million for the third quarter of 2026, compared to a net income of $45.4 million in the prior year period, primarily due to a significant decrease in the non-cash gain from the change in fair value of warrant liabilities. Operating expenses increased substantially to $25.9 million as the company ramped up research and development activities.
Arrow Electronics reported a significant increase in sales to $10.72 billion for the quarter ended October 3, 2026, compared to $7.71 billion in the prior-year period. Consolidated net income rose to $318.5 million, driven by strong performance in its Global Components and Global ECS segments, while the company maintained a robust balance sheet with total assets of $45.05 billion.
Payoneer Global Inc. reported third quarter 2026 financial results, featuring 2% revenue growth to $276.9 million and a 13% increase in total volume to $25.3 billion. The company highlighted significant momentum in its B2B segment, where volume grew 59% year-over-year, and noted that shareholders approved the pending merger with Nuvei in September 2026.
“Payoneer’s Q3 results show our upmarket strategy is working: B2B volume growth accelerated to 59% year-over-year, ARPU ex. interest expanded 20%+ year-over-year for a 9th consecutive quarter, and the percentage of our revenue from larger customers continues to grow.”
John Caplan, Chief Executive Officer
“We continue to work towards a targeted mid-2027 close of the Nuvei transaction. We received shareholder approval in September and are making progress with obtaining necessary regulatory approvals.”
Dyne Therapeutics reported Q3 2026 financial results, highlighting a cash position of $684.1 million to support operations into late 2026. The company is preparing for a potential Q1 2027 U.S. launch of z-rostudirsen for DMD, which is currently under FDA priority review with a PDUFA date of January 21, 2027.
Term
Q3 2026
“As we work toward potential commercialization, we are investing across multiple programs with the goal of unlocking the full value of our FORCE platform. This includes preparations for the potential U.S. launch of z-rostudirsen for exon 51 DMD, if approved, and topline data from the registrational expansion cohort of the ACHIEVE trial for z-basivarsen in DM1, both expected in the first quarter of 2027.”
John Cox, president and chief executive officer of Dyne
Advanced Flower Capital Inc. reported its third quarter 2026 financial results, highlighting a GAAP net investment income of $3.5 million and a net asset value (NAV) per share of $8.55. The company also repurchased approximately $1.0 million of its common stock during the quarter as part of its $5.0 million share repurchase program.
“AFC earned net investment income of $0.16 per share and grew NAV per share by $0.30 to $8.55. During the quarter, we repurchased approximately $1.0 million of our shares at roughly a 58% discount to NAV, adding $0.06 per share to NAV and bringing year-to-date accretion to $0.24. We will continue to allocate capital where it earns the best risk-adjusted return.”
Cabaletta Bio is a late-stage clinical biotechnology company focused on autoimmune diseases, specifically advancing its Phase 1/2 RESET clinical trials for rese-cel. As of October 30, 2026, the company reported 215,720,392 shares of common stock outstanding and continues to incur significant losses to fund its R&D and manufacturing partnerships with Lonza and Cellares.
Collegium Pharmaceutical reported net income of $21.8 million for the third quarter of 2026, a decrease from $31.5 million in the prior year period, despite a slight increase in product revenues to $216.3 million. The company completed the acquisition of Azstarys during the nine-month period, contributing to a significant increase in total assets to $2.1 billion and a rise in operating expenses due to higher selling, general, and administrative costs.
Lucky Strike Entertainment Corp reported total revenues of $302.6 million for the quarter ended September 27, 2026, a slight increase from $292.3 million in the prior year. However, the company saw its net loss widen to $25.7 million compared to $13.8 million previously, primarily driven by higher income tax expenses and increased selling, general, and administrative costs.
MACOM reported record fiscal fourth quarter revenue of $424.8 million, up 62.7% year-over-year, and full-year revenue of $1.33 billion. The company achieved significant profitability improvements with fiscal year GAAP net income of $335.3 million compared to a net loss in the prior year. Management provided strong guidance for the first quarter of fiscal 2027, expecting continued revenue growth and margin expansion.
Term
FY2026
“We had a strong fiscal year 2026 and look forward to continued growth in fiscal 2027”
Stephen G. Daly, President and Chief Executive Officer
Sphere Entertainment reported Q3 2026 revenues of $274.3 million, a 4% increase year-over-year, driven by growth in the Sphere segment. The company reported an operating loss of $240.6 million, primarily due to results at MSG Networks, while adjusted operating income rose 8% to $39.2 million.
Term
Q3 2026
“With today’s results, our Sphere segment remains on track to deliver substantial growth this calendar year. Looking ahead, we continue to make progress on our long-term vision for Sphere, including a global network of venues and a growing slate of original content.”
Collegium Pharmaceutical reported record Q3 2026 net revenue of $216.3 million, driven by strong performance in its ADHD portfolio, including record JORNAY PM sales and the first full quarter of AZSTARYS revenue. The company reaffirmed its full-year 2026 financial guidance and expects to complete its $50 million accelerated share repurchase program by year-end.
Term
Q3 2026
“We continued to see strong demand across our ADHD portfolio, supported by expanded commercial efforts heading into the back-to-school season. JORNAY PM reached record revenues, prescriptions and prescriber adoption, with quarterly net revenue growing 24% year-over-year.”
Vikram Karnani, President and Chief Executive Officer
“We generated a record $216.3 million in quarterly net revenue and $121.6 million in adjusted EBITDA, with our ADHD franchise now contributing more than 36% of total revenue.”
Cronos Group reported a significant increase in net revenue to $63.5 million for Q3 2026, up from $36.3 million in the prior year period, driven by growth in cannabis sales. The company achieved an operating income of $9.0 million for the quarter, a substantial improvement from the operating loss of $0.5 million in Q3 2025, while maintaining a strong cash and short-term investment position of approximately $741 million.
Sonida Senior Living reported third-quarter 2026 results featuring a 15.6% increase in same-store SHOP Net Operating Income and a 200 basis point increase in occupancy to 88.6%. The company also highlighted significant acquisition activity, including the purchase of six communities in October for $135.5 million and the utilization of its ATM program to raise $39.2 million in net proceeds during the quarter.
Term
Q3 2026
“Our third quarter results demonstrate the strength of the operating platform we have built and the quality of our real estate portfolio, with continued occupancy growth translating into meaningful margin expansion and NOI growth.”
Brandon Ribar, President and Chief Executive Officer
Arrow Electronics reported record third quarter 2026 results, with revenue of $10.7 billion, a 39% increase year-over-year. The company's performance was driven by strong demand in both its Global Components and Global Enterprise Computing Solutions segments, particularly in AI, cloud, and cybersecurity infrastructure.
Term
Q3 2026
“Arrow delivered record quarterly revenue and EPS in the third quarter, with strong momentum across both our Global Components and Global Enterprise Computing Solutions businesses, demonstrating the power of our diversified business model.”
Bill Austen, Arrow’s interim chief executive officer
“Global Enterprise Computing Solutions also experienced robust demand as customers continue to modernize their technology environments through investments in AI, cloud, cybersecurity and hybrid infrastructure solutions.”
Bill Austen, Arrow’s interim chief executive officer
Cronos Group reported record Q3 2026 financial results, with net revenue increasing 75% year-over-year to $63.5 million. The company achieved record performance in Canada, Israel, and Germany, while maintaining a strong balance sheet and continuing its share repurchase program.
Term
Q3 2026
“Cronos organically achieved records across net revenue, gross profit, and Adjusted EBITDA for the second consecutive quarter, while at the same time reducing shares outstanding.”
Mike Gorenstein, Chairman, President and CEO
“Our strategic focus on the development and production of market-leading borderless products continues to pay off, reflected in another record quarter of results.”
Twin Vee PowerCats reported a net loss of $3,013,052 for the quarter ended September 30, 2026, compared to a loss of $2,755,513 in the prior year period. Net sales decreased to $2,772,092 from $3,428,977, while the company underwent a significant one-for-37 reverse stock split in May 2026.
Lucky Strike Entertainment reported Q1 2027 revenue of $302.6 million, a 3.5% increase year-over-year, despite a 2.6% decline in same-store revenue. The company reported a net loss of $25.7 million and announced the suspension of its quarterly dividend to prioritize debt reduction and capital allocation.
Term
Q1 2027
“Revenue grew in the first quarter, helped by our first full summer with two new water parks, and while same-store revenue was down, it improved every month and September comped positive.”
Thomas Shannon, Founder and CEO
“Capital spending in the quarter was the lowest in five years, and we expect the full year at roughly half its fiscal 2024 peak. With capital spending down, no acquisitions and lower litigation costs, we expect to direct meaningful free cash flow, plus proceeds from a few non-core asset sales, to debt reduction.”
Installed Building Products reported record Q3 2026 net revenue of $808.4 million, a 3.9% increase year-over-year, despite softness in residential construction. The company also declared a quarterly dividend of $0.39 per share and noted the completion of four acquisitions during the quarter adding $22 million in annual revenue.
“During the third quarter, our team stayed focused on delivering a high level of installation service to our customers. Despite continued softness in residential construction activity, our same branch sales performance continued to outperform underlying market trends reflecting market share gains and the strength of our customer relationships across our branch network.”
Jeff Edwards, Chairman and Chief Executive Officer
“While affordability and consumer confidence remain headwinds for single-family construction, we continue to focus on commercial growth, acquisition integration, operational efficiency initiatives, and disciplined capital allocation.”
Jeff Edwards, Chairman and Chief Executive Officer
Black Spade Acquisition III Co reported net income of $2,115,385 for the nine months ended September 30, 2026, primarily driven by $4,573,722 in interest earned on cash held in its Trust Account. As a shell company, it maintains significant liquidity with $177,073,722 in the Trust Account to support a future business combination.
For the nine months ended September 30, 2026, Envoy Medical reported a net loss of $14.3 million, an improvement from the $17.2 million loss in the prior year period. The company strengthened its balance sheet through a February 2026 offering, increasing cash to $14.6 million and significantly reducing its stockholders' deficit.
Cabaletta Bio reported third quarter 2026 financial results, highlighting a cash position of $299.4 million which extends its operational runway into Q1 2028. The company announced plans for a BLA submission for rese-cel in myositis in Q1 2028 and initiated a second registrational study in systemic sclerosis. Management noted a recent increase in enrollment activity following a slower period in Q3 2026.
Term
Q3 2026
“We are encouraged by the favorable benefit-risk profile observed with rese-cel to date as we made deliberate choices, including construct design, standard and well-characterized manufacturing, and weight-based dosing, from the outset of its development to prioritize patient safety.”
Steven Nichtberger, M.D., Chief Executive Officer of Cabaletta
“We are now seeing increased enrollment and screening activity, with multiple patients enrolled in the past few weeks in the registrational adult myositis study, after a slower period in 3Q26 that we believe was influenced by patient and physician caution following recently reported safety events from others in the field.”
Steven Nichtberger, M.D., Chief Executive Officer of Cabaletta
Advanced Flower Capital Inc. reported incentive fees on net investment income of $0.8 million and $2.5 million for the three and nine months ended September 30, 2026, respectively. The company transitioned to a BDC structure on January 1, 2026, implementing a new advisory agreement with a 1.00% management fee on certain gross assets and a 17.5% incentive fee structure.
Graham Corp reported net sales of $69.8 million for the quarter ended September 30, 2026, a 6% increase over the prior year period. Net income grew significantly to $4.6 million, or $0.39 per diluted share, driven by improved gross margins and a substantial increase in cash and cash equivalents to $71.4 million following a common stock issuance.
Curtiss-Wright reported strong third quarter 2026 results with sales increasing 10% to $953 million and adjusted diluted EPS rising 16% to $3.94. Driven by robust demand in defense electronics and commercial nuclear solutions, the company raised its full-year 2026 guidance for sales, operating income, and EPS.
Term
Q3 2026
“Curtiss-Wright delivered a strong third quarter, highlighted by double-digit growth in both revenue and operating income, and mid-teens growth in adjusted diluted EPS, as we continue to execute on the strength of our product portfolio.”
Lynn M. Bamford, Chair and CEO
“Based on our strong year-to-date performance, we have raised our full-year guidance for all major financial metrics. We now anticipate sales growth of 8% to 10%, along with improved profitability across all three segments, as our Pivot to Growth Strategy continues to build momentum.”
Genie Energy reported third quarter 2026 results with net income increasing to $10.2 million ($0.39 per share) from $6.4 million in the prior year. While revenue decreased 8% to $127.2 million, Adjusted EBITDA grew 67% to $13.7 million, driven by normalized market conditions and gross margin expansion in the retail energy segment.
Term
Q3 2026
“Genie delivered solid bottom line gains in the third quarter versus the year-ago quarter. Income from operations climbed 72% year-over-year to $12.7 million and EPS increased by $0.14 to $0.39 per share.”
Michael Stein, Chief Executive Officer
“Adjusted EBITDA increased 67% to $13.7 million, putting us in a position to overcome the impacts of the challenging retail energy markets at the start of the year. We expect to reach our 2026 guidance of $32.5 to $40.0 million in Adjusted EBITDA.”
International Seaways reported record third quarter 2026 net income of $344 million, driven by exceptional tanker market conditions and a $53 million gain from a vessel sale. The company declared a combined dividend of $5.05 per share and completed the acquisition of Bruton Limited, adding four newbuilding VLCCs to its fleet.
Term
Q3 2026
“We delivered record quarterly net income, reflecting both exceptional tanker market conditions and the benefits of our long-term approach to fleet investment and capital allocation. While tanker markets were already strong earlier in the summer, rates surged to remarkable levels toward the end of the quarter. Our ability to capitalize on this extraordinary market reflects more than just favorable conditions; it is the result of years of disciplined capital allocation, fleet renewal and growth, all while strengthening our financial position and returning substantial capital to our shareholders.”
Lois K. Zabrocky, International Seaways President and CEO
“Our strong cash generation and financial position provide Seaways with considerable optionality in capital allocation. The completion of the Bruton transaction demonstrates our disciplined approach to deploying capital, using our shares as currency for growth while maintaining significant financial resources for futu”
The Middleby Corporation announced that Timothy J. FitzGerald will transition out of his role as CEO and step down from the Board effective March 31, 2027. Steven P. Spittle, the current Chief Commercial Officer, has been promoted to President effective immediately and will succeed FitzGerald as CEO on April 1, 2027.
Palvella Therapeutics reported third quarter 2026 financial results and provided a corporate update, highlighting the FDA's acceptance and Priority Review of its NDA for QTORIN™ rapamycin in microcystic lymphatic malformations. The company ended the quarter with $236.7 million in cash and is preparing for a potential U.S. commercial launch in the first half of 2027 following a February 28, 2027 PDUFA date.
Term
Q3 2026
“With the FDA’s acceptance of our NDA for QTORIN™ rapamycin in microcystic lymphatic malformations and granting of Priority Review, we believe we are closer than ever to bringing our first therapy to patients.”
Wes Kaupinen, Founder and Chief Executive Officer
“Our focus is clear: successfully obtain FDA approval and bring our first therapy to patients, advance multiple additional QTORIN™ programs to approval, and build the leading company addressing serious, rare skin diseases and vascular anomalies.”